Citations

Mayo Clinic

Showing 10 of 108523 citations.

Multisystem Imaging Manifestations of Kidney Failure
Suman, Garima , Vijay, Kanupriya , Venugopal, Nitin , Mansoori, Bahar , Agarwal, Amit , Rajiah, Prabhakar , Vijay, Kanupriya , Venugopal, Nitin , Mansoori, Bahar , Chalian, Majid , Agarwal, Amit Kumar , Rajiah, Prabhakar

RadioGraphics | July 25, 2024 | Volume: 44 | Issue: 8 | Pages: No page available

10.1148/rg.230124 | PMID 39052499 Get It

Effect of Aromatherapy on Perceived Mental Health Parameters for Academic Department Workers Working From Home During the COVID-19 Pandemic: A Pilot Study
Cutshall, Susanne M. , Mallory, Molly J., Noehl, Shelley M., Soderlind, Jennifer N., Nanda, S. , Bauer, Brent A. , Wahner‐Roedler, Dietlind L. , Mallory, Molly , Nanda, Sanjeev , Bauer, Brent A , Wahner-Roedler, Dietlind L , Fischer, Karen M.

Global Advances in Integrative Medicine and Health | July 25, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/27536130241267748 | PMID 39070282 Get It

Background Before the COVID-19 pandemic began, medical staff and academic department workers reported increasing levels of stress and burnout because of strain on the health care system. The COVID-19 pandemic exacerbated this strain and introduced several novel stressors, which included transitioning to remote work. Safe and scalable strategies are needed to help health care workers cope with these stressors. Aromatherapy may help address this need. Objectives To assess the effect of 2 aromatherapy interventions (essential oil blends termed STILL and FOCUS) on perceived mental/psychological health parameters for academic department workers working from home during the COVID-19 pandemic. Methods Participants were advised to use STILL for 5 days (Monday through Friday). After a 2-day washout period (Saturday and Sunday), participants were instructed to use FOCUS for 5 days (Monday through Friday). Participants completed a visual analog scale survey evaluating restlessness, fatigue, anxiety, stress, happiness, energy, relaxation, calmness, and well-being before and after each of the 2 intervention periods. Results Twenty academic department remote workers participated in the study. Mental/psychological health surveys were completed by 6 participants before and after using STILL and by 10 before and after using FOCUS. Five participants answered all survey questions before and after both interventions. Although mean (SD) perceived stress scores improved after both the STILL (4.3 [2.3] vs 1.8 [1.7], P = .03) and FOCUS (2.9 [2.3] vs 1.5 [1.4], P = .02) interventions, this improvement was not statistically significant after Bonferroni correction (adjusted α = .006). Most participants (73.3%) reported that participating in the study was worthwhile, and 81.3% indicated that they would recommend aromatherapy to others. Conclusions The STILL and FOCUS aromatherapy interventions did not significantly improve mental/psychological health parameters for remote academic department workers, although perceived stress was marginally improved and participants reported a perceived benefit from using aromatherapy.
Editorial for “Self‐Gated Radial Free‐Breathing Liver MR Elastography: Assessment of Technical Performance in Children at 3T”
Ehman, Richard L. , Ehman, Richard

Journal of Magnetic Resonance Imaging | July 25, 2024 | Volume: 61 | Issue: 3 | Pages: 1284-1285

10.1002/jmri.29542 | PMID 39052251 Get It

Identification of eupneic breathing using machine learning
Khurram, Obaid U. , Mantilla, Carlos B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B , Khurram, Obaid U

Journal of Neurophysiology | July 25, 2024 | Volume: 132 | Issue: 3 | Pages: 678-684

10.1152/jn.00230.2024 | PMID 39052237 Get It

The heterogeneity of diaphragm muscle (DIAm) activity in awake animals reflects real motor behavior diversity but makes assessments of eupneic breathing challenging. The present article uses an unsupervised machine learning model to identify eupneic breathing amidst a deluge of different DIAm electromyography (EMG) burst patterns in awake rats. This technique offers a scalable and reliable tool that improves efficiency of DIAm EMG analysis and minimizes potential sources of bias.
Noncontrast MR Lymphangiography to Identify Progression of Lymphatic Abnormalities over the Course of Fontan Completion
Collins, Jeremy D. , Thompson, Scott M. , Collins, Jeremy , Thompson, Scott

Radiology: Cardiothoracic Imaging | July 25, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1148/ryct.240201 | PMID 39051879 Get It

The Difficulty Implementing Evidence-Based Practice in the Perioperative Setting
Milam, Adam J. , Bonner, Timethia , Burton, Brittany N. , Youssef, Mohanad R. , Troianos, Christopher A. , Pittet, Jean‐François , Milam, Adam J , Williams, Brittney , Smith, Randi Nicole , Cannesson, Maxime P.

Anesthesia & Analgesia | July 25, 2024 | Volume: 139 | Issue: 4 | Pages: 874-880

10.1213/ane.0000000000006916 | PMID 39052524 Get It

BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Shevach, Jeffrey , Castro, Elena , Couch, Fergus J. , Domchek, Susan M., Eeles, Rosalind A. , Lin, Daniel W., Morgan, Todd M. , Offit, Kenneth, Schaeffer, Edward M. , Szymaniak, Brittany M. , Eeles, Rosalind A , Morgan, Todd M , Cheng, Heather H. , Couch, Fergus J. , Giri, Veda N. , Hall, Michael J. , King, Mary‐Claire , Lin, Daniel W., Loeb, Stacy , Offit, Kenneth, Pritchard, Colin C. , Vassy, Jason L. , Katona, Bryson W , Maxwell, Kara N.

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1272

10.1001/jamaoncol.2024.2185 | PMID 39052257 Get It

Importance Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. Observations This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. Conclusions and Relevance Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer
Ross, Helen J. , Kozono, David , Wang, Xiaofei F., Urbanic, James J., Nelson, Garth D. , Byun, Woo Yul , Talabere, Tiffany, DuFrane, Carter, Bāra, Ilze, Schulze, Katja , Brockman, Michelle, Gao, Junheng , Stinchcombe, Thomas E. , Kozono, David E , Williams, Terence M. , Carbone, David Paul , Chung, Dongjun , Robb, Ryan N. , Vokes, Everett E.

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1212

10.1001/jamaoncol.2024.1897 | PMID 39052256 Get It

Importance Outcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab prior to CRT may allow more patients to benefit from immunotherapy. Objective To evaluate clinical outcomes of patients treated with atezolizumab before and after CRT for unresectable stage III NSCLC. Design, Setting, and Participants This single-cohort, phase II, nonrandomized controlled trial was conducted at 11 US sites. Patients with pathologically confirmed, unresectable stage III NSCLC who were treatment naive and had good performance status were enrolled between January 3, 2018, and July 24, 2019. Data were locked on March 21, 2023. Interventions Patients received four 21-day cycles of atezolizumab, 1200 mg intravenously, with therapy administered on day 1 of each cycle. Patients not experiencing tumor progression continued to CRT (60 Gy to involved fields) concurrent with weekly carboplatin area under the curve of 2 and paclitaxel, 50 mg/m 2 , followed by planned consolidation carboplatin area under the curve of 6 and paclitaxel, 200 mg/m 2 , for two 21-day cycles. Patients not experiencing progression continued atezolizumab, 1200 mg, every 21 days to complete 1 year of therapy. Main Outcomes and Measures The primary end point was the disease control rate at 12 weeks. Secondary end points were progression-free survival, overall survival, overall response rate, safety, and translational science end points. Results A total of 62 patients (median [range] age, 63.9 [38.1-86.5] years; 32 female [51.6%]) were enrolled and received at least 1 dose of atezolizumab. The disease control rate at 12 weeks was 74.2% (80% CI, 65.7%-81.4%). Median progression-free survival was 30.0 months (95% CI, 15.8 to not evaluable), and the median overall survival was not reached. The overall survival rate at 24 months was 73.7% (95% CI, 63.4%-85.7%), and the overall response rate was 66.2%. Seventeen patients (27.4%) experienced grade 3 or higher immune-related adverse events, including 1 with grade 5 pneumonitis and 1 with grade 4 Guillain-Barré syndrome. Thirty patients (48.4%) experienced grade 3 or higher treatment-related adverse events. Conclusions and Relevance These findings suggest that neoadjuvant atezolizumab merits further study based on safety and encouraging outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT03102242
Malignant Peripheral Nerve Sheath Tumor and Epitheloid Sarcoma Associated with Von Recklinghausen Disease: A Case Report
Sharma, Shriya , Sherpa, Pasang , Giri, Ganesh , Sherpa, Pasang

No container title available | July 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172190664.47256480/v1 Get It

Cardiometabolic Risk Markers in Children With Obesity and Variants in MC4R Pathway-related Genes
Salama, Mostafa , Hentz, Roland, Nofal, Alaa Al , Hassan, Sara, Ibrahim, Samar H. , Lteif, Aida, Creo, Ana L. , Pittock, Siobhán T. , Kumar, Seema , Vairo, Filippo , Creo, Ana , Pittock, Siobhan , Kumar, Seema , Salama, Mostafa , Al Nofal, Alaa , Ibrahim, Samar H , Vairo, Filippo Pinto e

Journal of the Endocrine Society | July 25, 2024 | Volume: 8 | Issue: 9 | Pages: No page available

10.1210/jendso/bvae137 | PMID 39109292 Get It

Abstract Context Variants in melanocortin 4 receptor (MC4R) pathway-related genes have been associated with obesity. The association of these variants with cardiometabolic parameters are not fully known. Objective We compared the severity of obesity and cardiometabolic risk markers in children with MC4R pathway-related clinically reported genetic variants relative to children without these variants. Methods A retrospective chart review was performed in children with obesity who underwent multigene panel testing for monogenic obesity. Results Data on a total of 104 children were examined, with 93 (89%) identified as White. Thirty-nine (37.5%) patients had clinically reported variants in the MC4R pathway, and the remaining 65 patients did not have reported MC4R pathway-related variants. Among the MC4R-related variants, PCSK1 risk alleles were most common, reported in 15 children (14%). The maximum body mass index percent of the 95th percentile was not different between groups (P = .116). Low-density lipoprotein cholesterol (LDL-C) was not different between groups (P = .132). However, subgroup analysis demonstrated higher LDL cholesterol in children with the PCSK1 c.661A>G risk allele relative to those with MC4R-related variant of uncertain significance (P = .047), negative genetic testing (P = .012), and those with non-MC4R related variants (P = .048). The blood pressure, fasting glucose, hemoglobin A1C, total cholesterol, alanine transaminase, and high-density lipoprotein cholesterol were not different between groups. Conclusion Variants in the MC4R pathway-related genes were not associated with severity of obesity and cardiometabolic risk markers except for the c.661A>G PCSK1 risk allele, which was associated with higher LDL-C levels.